The European Hematology Association (EHA) congress was held in Frankfurt, Germany, on June 8, and our APLUSA experts had the pleasure of exhibiting at the 4-day event.
EHA Congress promotes excellence in patient care, research, and education in hematology.
.png?width=1408&height=923&name=APLUSA%20at%20EHA2023%20(2).png)
On this occasion, Dr. Nicolas BLIN, specialist in Hematology at Nantes University Hospital, accompanied our experts and had the opportunity to present the poster he co-created with our APLUSA experts Melissa YILMAZ and Siegfried ERTL.
Discover our poster: ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.
During the Friday evening poster session, Dr. BLIN took the time to present the results in a detailed video presentation. To find out more about our multiple myeloma poster, you can now access the full video below and learn more about our data from real-world study!
EHA-post webinar is available!
After the congress, we've held a webinar with Dr. Nicolas BLIN who highlighted the key moments of the EHA.
Co-moderated by our APLUSA experts Melissa YILMAZ and Siegfried ERTL, Dr. BLIN presented the latest news on hematology, commented some abstracts based on ongoing clinical trials and shared his thoughts on different hot topics in hematology (Multiple Myeloma, Acute Myeloid Leukemia, Myelofibrosis, bispecific antibodies, CAR T cell therapies, etc.).
More about multiple myeloma?
MMsyndiTrack™, our Multiple Myeloma (MM) syndicated study, includes all recent advances in MM treatment developed across our track record of more than 12 years studying this treatment area.
We offer subscriptions to our real-world data providing insights and the latest understanding of changing paradigms in the treatment of Multiple Myeloma.
The main objective of this study is to monitor the evolution of disease management among Multiple Myeloma patients.
